At the time of writing, Alnylam Pharmaceuticals Inc [ALNY] stock is trading at $253.35, up 0.94%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ALNY shares have gain 8.14% over the last week, with a monthly amount drifted -11.70%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Alnylam Pharmaceuticals Inc [NASDAQ: ALNY] stock has seen the most recent analyst activity on November 12, 2024, when Wolfe Research downgraded its rating to a Underperform. On August 16, 2024, upgrade upgraded it’s rating to Buy and revised its price target to $370 on the stock. Goldman downgraded its rating to a Neutral but stick to its price target of $173 on February 16, 2024. Wolfe Research initiated its recommendation with a Peer Perform. Wells Fargo started tracking with a Equal Weight rating for this stock on December 08, 2023, and assigned it a price target of $171. In a note dated December 08, 2023, Wells Fargo initiated an Equal Weight rating.
For the past year, the stock price of Alnylam Pharmaceuticals Inc fluctuated between $141.98 and $304.39. Currently, Wall Street analysts expect the stock to reach $254.21 within the next 12 months. Alnylam Pharmaceuticals Inc [NASDAQ: ALNY] shares were valued at $253.35 at the most recent close of the market. An investor can expect a potential return of 0.34% based on the average ALNY price forecast.
Analyzing the ALNY fundamentals
According to Alnylam Pharmaceuticals Inc [NASDAQ:ALNY], the company’s sales were 2.09B for trailing twelve months, which represents an -33.26% plunge. Gross Profit Margin for this corporation currently stands at 0.85% with Operating Profit Margin at -0.09%, Pretax Profit Margin comes in at -0.15%, and Net Profit Margin reading is -0.16%. To continue investigating profitability, this company’s Return on Assets is posted at -0.08, Equity is 3.24 and Total Capital is -0.06. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 31.64.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 249.49 points at the first support level, and at 245.64 for the second support level. However, for the 1st resistance point, the stock is sitting at 255.47, and for the 2nd resistance point, it is at 257.60.
Ratios To Look Out For
It is important to note that Alnylam Pharmaceuticals Inc [NASDAQ:ALNY] has a current ratio of 2.75. As well, the Quick Ratio is 2.69, while the Cash Ratio is 0.9. Considering the valuation of this stock, the price to sales ratio is 15.60, the price to book ratio is 1008.88.
Transactions by insiders
Recent insider trading involved Greenstreet Yvonne, Chief Executive Officer, that happened on Aug 20 ’24 when 15000.0 shares were sold. Officer, Greenstreet Yvonne completed a deal on Aug 20 ’24 to buy 15000.0 shares. Meanwhile, CSO & EVP, Head of Research Fitzgerald Kevin Joseph sold 22025.0 shares on Aug 12 ’24.
